Cardiac Rehabilitation for Cardiac Amyloidosis
(CAPACITY Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, it mentions that participants should be on stable treatment for their cardiac amyloidosis or under active surveillance, which suggests you may continue your current medications.
Is cardiac rehabilitation safe for humans?
How is the Cardiac Rehabilitation treatment for Cardiac Amyloidosis different from other treatments?
Cardiac Rehabilitation for Cardiac Amyloidosis is unique because it combines structured exercise, risk factor management, psychological support, and nutrition counseling to improve heart health and overall well-being, unlike traditional treatments that may not address these aspects comprehensively. This approach is particularly beneficial for patients with cancer-related heart issues, as it helps counteract the negative effects of cancer therapies on the heart.12467
What data supports the effectiveness of the treatment Cardiac Rehabilitation for Cardiac Amyloidosis?
Cardiac rehabilitation has been shown to improve heart function and overall well-being in patients with heart conditions, such as after a heart attack, by including exercise, diet changes, and stress management. These components can help improve symptoms and quality of life, which may also benefit patients with cardiac amyloidosis.89101112
Who Is on the Research Team?
Jai Singh, MD
Principal Investigator
Wake Forest University Health Sciences
Are You a Good Fit for This Trial?
The CAPACITY study is for adults over 18 with mild to moderate heart failure who can exercise and commit to a cardiac rehab program. They should be on stable treatment or monitored for cardiac amyloidosis, have a life expectancy of at least 6 months, and be able to attend thrice-weekly sessions.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Testing
Baseline 6-minute walk test and cardiopulmonary exercise test (CPET) testing
Treatment
Supervised cardiac rehabilitation program including planned 3 one-hour sessions a week for a total of 12 weeks
Post-Intervention Testing
Post-intervention 6-minute walk test and CPET test performed within 2 weeks of completion of the 12-week program
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cardiac Rehabilitation
Cardiac Rehabilitation is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor